Menghan Gao
Overview
Explore the profile of Menghan Gao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang N, Gao M, Hu X, Wang P, Cheng Y, Wei H, et al.
Biomaterials
. 2025 Mar;
319:123214.
PMID: 40037208
Heart ischemic injury predominately causes mitochondrial dysfunction, leading to the accumulation of ROS and lactate. The ROS-associated DNA damage response (DDR) contributes to myocardial cell cycle arrest and the inhibition...
2.
Gao M, Liu B, Li J, Deng Y, Zhang Y, Zhang N, et al.
J Fungi (Basel)
. 2024 Dec;
10(12).
PMID: 39728363
Fungi are one of the major components of the eukaryotic microbial community in marine ecosystems, playing a significant role in organic matter cycling and food web dynamics. However, the diversity...
3.
Xiang G, Cao G, Gao M, Hu T, He W, Gu C, et al.
Front Cardiovasc Med
. 2024 Nov;
11:1382374.
PMID: 39507387
Objective: This study aims to explore the association between risk stratification and total occlusion (TO) of the culprit artery and multivessel disease (MVD) in patients with non-ST-segment-elevation myocardial infarction (NSTEMI)...
4.
Guo H, Wang H, Gao M, Deng H, Zhang Y, Gong J, et al.
Carbohydr Polym
. 2024 Sep;
344:122521.
PMID: 39218565
The combination of the standard platinum-based chemotherapy with EGFR-tyrosine kinase inhibitor Gefitinib (Gef) principally boosts the anticancer efficacy of advanced non-small cell lung cancer (NSCLC) through non-overlapping mechanisms of action,...
5.
Liu R, Hou W, Li J, Gou X, Gao M, Wang H, et al.
Int J Biol Macromol
. 2024 May;
269(Pt 1):132074.
PMID: 38705320
Treatment for triple negative breast cancer (TNBC) remains a huge challenge due to the lack of targeted therapeutics and tumor heterogenicity. Cisplatin (Cis) have demonstrated favorable therapeutic response in TNBC...
6.
Li Y, Long W, Zhang H, Zhao M, Gao M, Guo W, et al.
Int Immunopharmacol
. 2024 Mar;
131:111844.
PMID: 38503013
Objectives: Diabetic nephropathy (DN) is characterized by albuminuria and renal dysfunction caused by diabetes. At present there is no specific treatment for DN. Irbesartan (IRB) is an angiotensin receptor inhibitor...
7.
Jiang H, Yang S, Chen Z, Li D, Shan Y, Tao Y, et al.
Heliyon
. 2023 Dec;
9(11):e22284.
PMID: 38045122
Background: Glasgow prognostic score (GPS) is a reliable scoring system reflecting both nutritional and inflammatory factors. The association of inflammation and nutrition with contrast-associated acute kidney injury (CA-AKI) has been...
8.
Deng H, Yang X, Wang H, Gao M, Zhang Y, Liu R, et al.
Carbohydr Polym
. 2023 Nov;
325:121585.
PMID: 38008480
Tumor-associated macrophages (TAMs) have emerged as therapeutic interests in cancer nanomedicine because TAMs play a pivotal role in the immune microenvironment of solid tumors. Dextran and its derived nanocarriers are...
9.
Chai K, Wang C, Zhou J, Mu W, Gao M, Fan Z, et al.
Pharmacol Res
. 2023 Nov;
198:106987.
PMID: 37949332
Anticancer drugs have been developed with expectations to provide long-term or at least short-term survival benefits for patients with cancer. Unfortunately, drug therapy tends to provoke malignant biological and clinical...
10.
Chen L, Qiu W, Sun X, Gao M, Zhao Y, Li M, et al.
Gut
. 2023 Nov;
73(3):521-532.
PMID: 37945330
Objective: Different serum lipids and lipid-modifying targets should affect the risk of cholelithiasis differently, however, whether such effects are causal is still controversial and we aimed to answer this question....